The FDA cleared AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Datroway for first-line treatment of triple-negative breast cancer (TNBC) when patients are not candidates for PD-1/PD-L1 inhibitor therapy, giving the ADC a new position early in the treatment sequence. The agency’s approval was grounded in the Phase 3 TROPION-Breast02 trial, where Datroway improved overall survival versus investigator’s choice chemotherapy, with a hazard ratio of 0.79 (P=.0290). Separately, FDA also authorized Gilead’s hepatitis D therapy Hepcludex (bulevirtide) after addressing prior manufacturing and distribution issues. While not breast cancer-related, it reflects heightened FDA engagement with previously stalled inputs-to-approval programs. For TNBC specialists, Datroway’s approval expands the first-line arsenal for a difficult-to-treat population and strengthens TROP2-targeting competition in ADC-heavy development programs across multiple tumor types.